

Gabriele Imbalzano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10198430/publications.pdf>

Version: 2024-02-01

20
papers

310
citations

1163117

8
h-index

940533

16
g-index

20
all docs

20
docs citations

20
times ranked

431
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between sleep disorders and cognitive dysfunctions in non-demented patients with advanced Parkinson's disease. <i>Journal of Neurology</i> , 2022, 269, 1538-1545.	3.6	2
2	Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease. <i>Neurological Sciences</i> , 2022, 43, 3187-3193.	1.9	1
3	Time to onset and duration of botulinum toxin efficacy in movement disorders. <i>Journal of Neurology</i> , 2022, 269, 3706-3712.	3.6	11
4	SARS-CoV-2 vaccination, Parkinson's disease, and other movement disorders: case series and short literature review. <i>Neurological Sciences</i> , 2022, 43, 5165-5168.	1.9	8
5	Neurological comorbidity and severity of COVID-19. <i>Journal of Neurology</i> , 2021, 268, 762-769.	3.6	47
6	Low frequency subthalamic stimulation and event-related potentials in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 123-127.	2.2	4
7	Safety and efficacy of tolcapone in Parkinson's disease: systematic review. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 817-829.	1.9	24
8	Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials. <i>Frontiers in Neurology</i> , 2021, 12, 648532.	2.4	21
9	Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic. <i>Neurological Sciences</i> , 2021, , 1.	1.9	29
10	Deep brain stimulation outcomes in the malignant end of Parkinson's disease spectrum. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 5-9.	2.2	2
11	Neurological comorbidities and COVID-19-related case fatality: A cohort study. <i>Journal of the Neurological Sciences</i> , 2021, 428, 117610.	0.6	8
12	Early reversible leukoencephalopathy and unilateral sixth cranial nerve palsy in mild COVID-19 infection. <i>Neurological Sciences</i> , 2021, 42, 4899-4902.	1.9	7
13	Speech Impairment in Parkinson's Disease: Acoustic Analysis of Unvoiced Consonants in Italian Native Speakers. <i>IEEE Access</i> , 2021, 9, 166370-166381.	4.2	10
14	Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors. <i>Parkinsonism and Related Disorders</i> , 2020, 76, 98-103.	2.2	11
15	Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential. <i>Neurotherapeutics</i> , 2020, 17, 1736-1746.	4.4	20
16	Levodopa/Carbidopa Intestinal Gel Long-Term Outcome in Parkinson's Disease: Focus on Dyskinesia. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 930-939.	1.5	7
17	COVID-19 in Parkinson's disease: Report on prevalence and outcome. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 7-9.	2.2	42
18	Tuning deep brain stimulation related depression by frequency modulation: A case report. <i>Brain Stimulation</i> , 2020, 13, 1265-1267.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Video analysis of long-term effects of levodopa-carbidopa intestinal gel on gait and posture in advanced Parkinson's disease. <i>Neurological Sciences</i> , 2020, 41, 1927-1930.	1.9	6
20	Differential response to pallidal deep brain stimulation among monogenic dystonias: systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 426-433.	1.9	49